CLL-1 targeted immunotherapies
US12421315B2 · kind B2 · utility
0Cited by
14References
20Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 7, 2020 |
| Grant date | Sep 23, 2025 |
| Priority date | — |
| Expiry date | Jan 22, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.